Immune-Onc Therapeutics
Xiao Min Schebye has been working in the field of Immuno-Oncology for over two decades. Xiao Min began their career in 1999 as a Senior Scientist at Incyte, before moving to Merck in 2001 as a Principal Scientist. In 2012, they joined ChemPartner as Senior Fellow and Head of Immunology, and in 2014 they were appointed Associate Director of Immuno-Oncology Discovery at Bristol-Myers Squibb. Most recently, they were appointed Senior Director at Immune-Onc Therapeutics in 2022.
Xiao Min Schebye completed a Postdoctoral fellowship at Stanford University, a PhD in Biology from the University of Wisconsin-Madison, and a MD in Medicine from Shanghai Jiao Tong University.
Immune-Onc Therapeutics
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.